# US 2025/0152665 A1 · Mutant Peptides And Methods Of Treating Subjects Using The Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152665 A1
- Document ID: US20250152665A1
- Status: Published application
- Kind: A1
- Application number: 18/957,407
- Filed: 2024-11-22
- Published: 2025-05-15
- Earliest claimed: 2015-08-28
- Assignees: Prince Biotech, LLC
- Applicants: Prince Biotech, LLC
- Inventors: Eytan R. Barnea
- Web page: https://patentgrep.com/patent/US20250152665A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/06: for tuberculosis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating autoimmune disease using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.

## Claims

### Claim 1

A composition comprising a PIF analog comprising an amino acid sequence that is at least 93% homologous to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the PIF analog comprises an amino acid sequence that is at least 93% homologous to SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising:
i) a therapeutically effective amount of the composition of claim 1 or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the PIF analog comprises an amino acid sequence that is at least 93% homologous to SEQ ID NO: 8, SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the therapeutically effective amount is from about 1 milligram to about 4 grams.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, wherein the therapeutically effective amount is about 70 milligrams.

### Claim 7

A method of treating or preventing autoimmune disease in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The method of claim 7, wherein the pharmaceutically acceptable carrier is sterile and pyrogen-free water or sterile and pyrogen-free Lactated ringer's solution.

### Claim 9 (depends on 7)

The method of claim 7, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 1.0 mg/kg, wherein kg is kilograms of the subject and mg is milligrams of the therapeutically effective dose.

### Claim 10 (depends on 7)

The method of claim 7, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5.0 mg/kg, wherein kg is kilograms of the subject and mg is milligrams of the therapeutically effective dose.

### Claim 11 (depends on 7)

The method of claim 7, wherein the PIF analog is any one or plurality of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and/or SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the step of administering to the subject at least one pharmaceutical composition comprises administering a therapeutically effective amount of the PIF analog or pharmaceutically acceptable salt thereof from about 0.001 mg/kg to about 200 mg/kg.

### Claim 13 (depends on 7)

The method of claim 7, wherein the step of administering to the subject at least one pharmaceutical composition comprises administering a therapeutically effective amount of the PIF analog or pharmaceutically acceptable salt thereof from about 0.5 mg/kg to about 5 mg/kg, wherein kg is kilograms of the subject and mg is milligrams of the therapeutically effective dose.

### Claim 14

A method of treating or preventing diabetes in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pharmaceutically acceptable carrier is sterile and pyrogen-free water or sterile and pyrogen-free Lactated ringer's solution.

### Claim 16 (depends on 14)

The method of claim 14, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 1.0 mg/kg, wherein kg is kilograms of the subject and mg is milligrams of the therapeutically effective dose.

### Claim 17 (depends on 14)

The method of claim 14, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5.0 mg/kg, wherein kg is kilograms of the subject and mg is milligrams of the therapeutically effective dose.

### Claim 18 (depends on 14)

The method of claim 14, wherein the PIF analog is any one or plurality of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and/or SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 14)

The method of claim 14, wherein the at least one pharmaceutical composition is administered via intravenously, intramuscularly, topically, intradermally, transmucosally, subcutaneously, sublingually, transdermally, orally, buccally, intraocularly, intravaginally, intrarectally, intraductally, intrathecally, subdurally, extradurally, intraventricularly, intraarticularly, intraperitoneally, into the pleural cavity, by inhalation, by depot injections, or by implants.

### Claim 20

A method of binding an insulin degrading enzyme (IDE) in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier.

### Claim 21 (depends on 20)

The method of claim 20, wherein the PIF analog is any one or plurality of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and/or SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.
